Actively Recruiting
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
Led by University of California, Davis · Updated on 2026-02-02
51
Participants Needed
2
Research Sites
208 weeks
Total Duration
On this page
Sponsors
U
University of California, Davis
Lead Sponsor
N
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.
CONDITIONS
Official Title
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Able to understand the study and willing to sign informed consent
- Willing and able to follow all study procedures
- For those who can have children, willing to use effective double barrier contraception during the study and 1 day after last radiotracer use
- Previous diagnosis of COVID-19 confirmed by positive test or participant attestation
- COVID-19 symptoms or positive test at least 3 months before baseline visit
- Able to travel to study sites in San Francisco or Sacramento
- Lab tests within 60 days showing adequate blood counts and liver and kidney function
- For PASC participants: at least 2 unexplained symptoms lasting 2 months or more including fatigue and cardiopulmonary or neurocognitive symptoms
- For control participants: full recovery from COVID-19 within 4-12 weeks with no new symptoms after recovery
You will not qualify if you...
- Serious health conditions that could affect study goals
- Immune system problems or diseases affecting imaging, including inflammatory, immune disorders, cancers, or chronic viral infections like HIV or hepatitis
- COVID-19 vaccination within 30 days before imaging
- Pregnant or nursing individuals
- Prior stem cell or organ transplant
- History of myelodysplasia or lymphoproliferative disease
- Active systemic autoimmune diseases not related to COVID-19
- Severe claustrophobia
- Participation in another PET scan research study within the last 12 months
- Body weight over 240 kg (529 pounds)
- Prisoners
- Life expectancy less than 24 months
- Recent use of certain medications like guanosine or cysteine analogs
- Any other reasons the investigator decides make participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
UC Davis EXPLORER Molecular Imaging Center
Sacramento, California, United States, 95816
Actively Recruiting
2
University of California San Francisco
San Francisco, California, United States, 94110
Actively Recruiting
Research Team
C
Clinical Research Team
CONTACT
N
Negar Omidvari, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here